Guardant Reports Record Q3 Sales And A Buy Back From Softbank
Executive Summary
Strong oncology sales have driven the company’s revenues to new heights, keeping it on target to meet its yearly revenue guidance.
You may also be interested in...
JPM 2022 Mid-Week IVD Roundup: Guardant, Illumina, Ortho Clinical, Thermo Fisher
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.
J&J Refines Direction For Ottava
Delays have plagued J&J's soft tissue surgical robot. However, the company has now solidified at least its near-term plan and hopes to commence trials later this year.
J&J Refines Direction For Ottava
Delays have plagued J&J's soft tissue surgical robot. However, the company has now solidified at least its near-term plan and hopes to commence trials later this year.